RESUMEN
This comparative study of the influence of cytoflavin and cardioxipin on the parameters of 24-hour arterial pressure monitoring in 56 patients with chronic cerebral circulation insufficiency, arterial hypertension and hypercholesterolemia included 32 women and 24 men aged 42-72 years divided into 3 groups matchedfor the stage of diseases, age, sex, severity of AH, total cholesterol level, and antihypertensive therapy. Patients of group 1 were treated without cytoflavin and cardioxipin. Those in group 2 received daily i/v droplet infusion of 10 mg/kg cardioxipin (20-30 droplets/min). Patients of group 3 were given daily i/v droplet infusion of 10 ml cytoflavin in 200 ml 0.9% sodium chloride solution for 10 days. 24-hour arterial pressure monitoring was used to estimate the influence of the two drugs on systolic and diastolic pressure, its daily rhythm, AP variability and frequency of elevation. The study showed that both therapeutic modalities improved daily AP rhythm as manifested in a significant increase of the number of patients with the dipper rhythm and a decrease in the number of systolic/diastolic non-dipper patients. Moreover cytoflavin significantly decreased the number of systolic over-dippers compared with control group.
Asunto(s)
Antihipertensivos/administración & dosificación , Presión Arterial/efectos de los fármacos , Monitoreo Ambulatorio de la Presión Arterial/métodos , Trastornos Cerebrovasculares/tratamiento farmacológico , Mononucleótido de Flavina/administración & dosificación , Hipercolesterolemia/tratamiento farmacológico , Hipertensión/tratamiento farmacológico , Inosina Difosfato/administración & dosificación , Niacinamida/administración & dosificación , Succinatos/administración & dosificación , Adulto , Anciano , Circulación Cerebrovascular/efectos de los fármacos , Trastornos Cerebrovasculares/complicaciones , Trastornos Cerebrovasculares/fisiopatología , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Hipercolesterolemia/complicaciones , Hipercolesterolemia/fisiopatología , Hipertensión/complicaciones , Hipertensión/fisiopatología , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
OBJECTIVE: To compare the effects of cytoflavin and cardioxipin on the emotional status of rats with experimental disturbance of lipid metabolism using the uplifted cruciform labyrinth method. MATERIAL AND METHODS: The disturbance of lipid metabolism was induced by the introduction of exogenic cholesterol-in -oil emulsion in dosage 40 mg /kg of body mass during 20 days. Pharmacological treatment was performed in the 11th day. The drugs were injected intraperitoneally during 10 days: cytoflavin in dose 1,75 ml/ kg (175 mg/kg with succinic acid), cardioxipin in dose 52,5 mg/kg. RESULTS AND CONCLUSION: Cytoflavin and cardioxipin caused the positive changes in the parameters of emotional status of rats in conditions of experimental dyslipidemia.
Asunto(s)
Ansiedad/prevención & control , Dislipidemias/psicología , Emociones/efectos de los fármacos , Mononucleótido de Flavina/administración & dosificación , Inosina Difosfato/administración & dosificación , Niacinamida/administración & dosificación , Picolinas/administración & dosificación , Succinatos/administración & dosificación , Animales , Modelos Animales de Enfermedad , Combinación de Medicamentos , Masculino , RatasRESUMEN
Comparative tests on nonlinear rats of both sex with model violation of lipid metabolism have been performed in order to study the effects of cytoflavin (1.75 ml/kg or 175 mg/kg with respect to succinic acid) and cardioxipin (52.5 mg/kg) on lipid peroxidation and antioxidant protection indices in the blood. It is established that these preparations cause a decrease in the content of malonic dialdehyde (MDA) in erythrocytes that results in increased antioxidant activity and lipid reserves for peroxidation in the blood.
Asunto(s)
Antioxidantes/metabolismo , Dislipidemias/tratamiento farmacológico , Eritrocitos/efectos de los fármacos , Mononucleótido de Flavina/farmacología , Inosina Difosfato/farmacología , Niacinamida/farmacología , Sustancias Protectoras/farmacología , Piridonas/farmacología , Succinatos/farmacología , Animales , Animales no Consanguíneos , Catalasa/sangre , Combinación de Medicamentos , Dislipidemias/sangre , Eritrocitos/química , Eritrocitos/metabolismo , Femenino , Peroxidación de Lípido/efectos de los fármacos , Masculino , Malondialdehído/antagonistas & inhibidores , Malondialdehído/sangre , Ratas , Superóxido Dismutasa/sangreRESUMEN
We studied the effect of dicarbamine and leucostim on myelopoiesis in experimental post-radiation bone marrow syndrome. Dicarbamine in different modes of administration and doses provided a high level of protection of proliferating hematopoietic precursors in the early period after radiation, which was reflected in a statistically significant decrease in the depth and duration of post-radiation deficit of cells, such as of granulocytes, lymphocytes, megakaryocytes and erythroid cells. The greatest effect of the drug appeared at a dose of 4 mg/kg (prophylactic administration) and a dose of 15 mg/kg (curative double dose). In the bone marrow of experimental animals leucostim prevented development of post-radiation deficit of granulocytes and lymphocytes to a lesser extent, than dicarbamine, and it was effective for erythroid cells and megakaryocytes.
Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/efectos de la radiación , Caproatos/farmacología , Factor Estimulante de Colonias de Granulocitos/farmacología , Células Madre Hematopoyéticas/efectos de los fármacos , Imidazoles/farmacología , Protectores contra Radiación/farmacología , Animales , Médula Ósea/efectos de los fármacos , Médula Ósea/efectos de la radiación , Caproatos/administración & dosificación , Relación Dosis-Respuesta a Droga , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Granulocitos/efectos de los fármacos , Granulocitos/efectos de la radiación , Células Madre Hematopoyéticas/efectos de la radiación , Imidazoles/administración & dosificación , Masculino , Megacariocitos/efectos de los fármacos , Megacariocitos/efectos de la radiación , Conejos , Protectores contra Radiación/administración & dosificación , Síndrome , Factores de TiempoRESUMEN
There was studied the effect of different doses of Dicarbamine by means of oral medical-prophylactic and medical administration on the peripheral blood of rabbits in conditions of experimental radiation damage to the blood system. The drug provided the safety of circulating red blood cells at rather high level, prevented the development of severe post-radiation thrombocytopenia, reduced post-radiation leukocytopenia, accelerated processes of recovery of peripheral blood leukocytes to the initial level by segmented neutrophils and lymphocytes.
Asunto(s)
Imidazoles/farmacología , Leucopenia/prevención & control , Traumatismos Experimentales por Radiación/sangre , Radiación Ionizante , Protectores contra Radiación/farmacología , Trombocitopenia/prevención & control , Animales , Caproatos , Leucopenia/etiología , Linfocitos/efectos de los fármacos , Linfocitos/efectos de la radiación , Masculino , Neutrófilos/efectos de los fármacos , Neutrófilos/efectos de la radiación , Conejos , Traumatismos Experimentales por Radiación/etiología , Trombocitopenia/etiologíaRESUMEN
There was studied the influence Dicarbamine and Leykostime on peripheral blood leukocyte composition of rabbits in experimental radiogenic damage to the blood system. Dicarbamine significantly insured the safety of circulating red blood cells, prevented the development of severe postradiation thrombocytopenia, reduced postradiation leukocytopenia, and accelerated the recovery of peripheral blood leukocytes to the initial level by segmented neutrophils and lymphocytes. Leukostime ensured the safety of peripheral blood leukocytes however was less effective than Dicarbamine to prevent postradiation deficit of circulating red blood cells and thrombocytes.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos/farmacología , Imidazoles/farmacología , Leucocitos/efectos de los fármacos , Leucocitos/efectos de la radiación , Leucopenia/prevención & control , Traumatismos Experimentales por Radiación/prevención & control , Protectores contra Radiación/farmacología , Animales , Plaquetas/efectos de los fármacos , Plaquetas/efectos de la radiación , Caproatos , Eritrocitos/efectos de los fármacos , Eritrocitos/efectos de la radiación , Filgrastim , Recuento de Leucocitos , Leucopenia/etiología , Linfocitos/efectos de los fármacos , Linfocitos/efectos de la radiación , Masculino , Conejos , Proteínas Recombinantes/farmacología , Trombocitopenia/etiología , Trombocitopenia/prevención & control , Factores de Tiempo , Resultado del TratamientoRESUMEN
The effect of dicarbamin on cellular composition of rabbits' venous blood in experimental post-radiation bone marrow syndrome was studied. The dicarbamin use has allowed to reduce depth and to shorten the duration of post-radiation leukocytopenia.
Asunto(s)
Médula Ósea/efectos de los fármacos , Médula Ósea/efectos de la radiación , Imidazoles/efectos adversos , Protectores contra Radiación/farmacología , Animales , Caproatos , Imidazoles/administración & dosificación , Masculino , Conejos , Síndrome , Resultado del TratamientoRESUMEN
The effect of dicarbamine on hemopoiesis in experimental post-irradiation bone-marrow syndrome was studied. The myeloprotective activity of the drug was established. It manifested in the protection of hematopoietic progenitor cells and stimulation of cell proliferation and differentiation in the bone marrow.
Asunto(s)
Médula Ósea/efectos de los fármacos , Médula Ósea/efectos de la radiación , Hematopoyesis/efectos de los fármacos , Células Madre Hematopoyéticas/efectos de los fármacos , Imidazoles/farmacología , Sustancias Protectoras/farmacología , Animales , Caproatos , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Hematopoyesis/efectos de la radiación , Células Madre Hematopoyéticas/efectos de la radiación , Conejos , SíndromeRESUMEN
The condition of the mucous membrane and lipid spectrum of tissue structures under the action of gastric ulcerogenic stress factors was studied on the background of administration of vitamin E, dimephosphon, and reamberin. The use of antioxidants, especially reamberin, led to the restoration of lipid metabolism and normalization of lipid peroxidation processes.
Asunto(s)
Antioxidantes/farmacología , Meglumina/análogos & derivados , Estrés Oxidativo/efectos de los fármacos , Úlcera Gástrica/metabolismo , Succinatos/farmacología , Animales , Catalasa/análisis , Catalasa/metabolismo , Cromatografía en Capa Delgada , Modelos Animales de Enfermedad , Femenino , Peroxidación de Lípido/efectos de los fármacos , Masculino , Malondialdehído/análisis , Meglumina/farmacología , Compuestos Organofosforados/farmacología , Fosfolipasas A2/análisis , Fosfolipasas A2/metabolismo , Ratas , Úlcera Gástrica/fisiopatología , Superóxido Dismutasa/análisis , Superóxido Dismutasa/metabolismo , Vitamina E/farmacologíaRESUMEN
The effect of reamberin on morphofunctional changes in the small intestine mucous membrane due to stress ulcerogenesis was studied. Normalization of the lipid modifications in the tissue structure, evident of the drug antiulcerous properties, was observed.
Asunto(s)
Mucosa Intestinal/efectos de los fármacos , Intestino Delgado/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Meglumina/análogos & derivados , Succinatos/uso terapéutico , Animales , Modelos Animales de Enfermedad , Úlcera Duodenal/tratamiento farmacológico , Femenino , Humanos , Mucosa Intestinal/patología , Intestino Delgado/patología , Masculino , Meglumina/uso terapéutico , Estrés Oxidativo/efectos de los fármacos , Ratas , Úlcera Gástrica/tratamiento farmacológicoRESUMEN
Effects of dicarbamin on the post-irradiation dynamics of leukocyte composition in the peripheral blood of mice have been studied upon oral administration of the drug in a single dose of 0.5, 5.0, 15.0, and 50.0 mg/kg. It is established that the drug doses of 5.0, 15.0, and 50.0 mg/kg produce statistically significant radioprotective effects. The leukocyte fall decreases due to segmented neutrophils and lymphocytes. In addition, the drug accelerates the process of restoration of the leukocyte cell numbers on the initial level.
Asunto(s)
Imidazoles/farmacología , Leucocitos/efectos de la radiación , Protectores contra Radiación/farmacología , Animales , Caproatos , Relación Dosis-Respuesta en la Radiación , Recuento de Leucocitos , Leucocitos/citología , Masculino , RatonesRESUMEN
The results of experiments on dogs showed that quaternidine, a quaternary ammonium derivative of trimecaine, produces a significant antiarrhythmogenic effect in cases of rhythm disorders in the late stage of a model myocardial infarction. For drugs administered in a single isotoxic dose, the therapeutic effect of quaternidine in animals with acute myocardial ischemia considerably exceeds the duration of action of lidocaine and trimecaine.
Asunto(s)
Antiarrítmicos/uso terapéutico , Compuestos de Amonio Cuaternario/uso terapéutico , Trimecaína/uso terapéutico , Complejos Prematuros Ventriculares/tratamiento farmacológico , Animales , Modelos Animales de Enfermedad , Perros , Electrocardiografía , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Quinidina/uso terapéutico , Trimecaína/análogos & derivados , Complejos Prematuros Ventriculares/fisiopatologíaRESUMEN
The results of experiments on cats and dogs showed that quaternidine, a quaternary ammonium derivative of trimecaine, exceeds the structural precursors (trimecaine and lidocaine), as well as the reference drugs quinidine and propranolol, in intensity of the antiarrhythmic action upon single administration on the occlusive and reperfusive arrhythmia models. The therapeutic effect of quaternidine in animals with acute myocardial ischemia lasts for about 8 h, which more than 20 times longer as compared to the duration of action of both lidocaine and trimecaine.